ClinicalTrials.gg
RecruitingNCT07207239TMS-DEP-2024Updated Nov 17, 2026

Effect of Theta-burst rTMS Therapy on the Clinical and Cognitive Symptoms of Patients With Therapy Resistant Depression and Response Prediction With Neuroimaging Methods.

An interventional study of repetative Transcranial Magnetic Stimulation (rTMS), theta-burst protocol in Transcranial Magnetic Stimulation, Repetitive and Depression - Major Depressive Disorder, sponsored by Semmelweis University. Recruiting at 1 site in Hungary. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Semmelweis University · Not applicable, Interventional, and Screening

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Nov 17, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The primary aim of the study is to find the combination of neuroimaging-related markers, demographics, and clinical characteristics that predict the response of patients with therapy-resistant depression to theta-burst rTMS treatment. The secondary aim is to monitor the cognitive effects of TMS therapy.

02

Conditions studied

  • Transcranial Magnetic Stimulation, Repetitive
  • Depression - Major Depressive Disorder

Keywords

  • TMS
  • therapy resistant depression
  • EEG
  • MRI
  • neuroimaging
03

In context

Depressive Disorder, Treatment-Resistant

450 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 148 are open to participants now.

This study's planned enrollment of 54 is close to the median of 58 across 373 interventional studies indexed under Depressive Disorder, Treatment-Resistant.

Browse Depressive Disorder, Treatment-Resistant studies →

Lead sponsor

Semmelweis University is the lead sponsor of 140 studies on the registry; 55 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. diagnosis of depression
  2. 18 years of age
  3. Beck depression inventory score above 12 (screening)
  4. MADRS score above 6 (baseline)

Exclusion criteria

Exclusion Criteria:

  1. serious cognitive impairment
  2. mental retardation
  3. history of head injury with loss of consciousness for more than 1 hour
  4. alcohol or drug abuse within the past 3 months
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    TB-rTMS

    Device: repetative Transcranial Magnetic Stimulation (rTMS), theta-burst protocol

Interventions

  • Devicerepetative Transcranial Magnetic Stimulation (rTMS), theta-burst protocol

    Theta-burst rTMS treatment stimulates the left Dorsolateral Prefrontal Cortex (DLPFC). The TBS parameters the investigators adopted follows the standard TBS protocols, with 3-pulse 50-Hz bursts given every 200 ms (at 5 Hz) and an intensity of 100% active motor threshold. The investigators plan to deliver 1800 stimuli to the left DLPFC daily in 9.5-minute blocks for four weeks.

06

What researchers measure

Primary outcomes

  1. Clinical symptoms

    The primary outcome measures are the clinical symptoms of depression measured by a clinician with the Montgomery-Åsberg Depression Rating Scale.

    Time frame: 120 days

Secondary outcomes

  1. Neuroimaging characteristics

    A secondary outcome measure is neuroimaging characteristics including the alpha peaks measured by EEG, the nonoscillatory component (1/f) calculated from resting EEG, and connectivity parameters measured by fMRI. These markers will play a part in response prediction.

    Time frame: 120 days

  2. Patient profile

    The patient profile encompasses demographics and clinical characteristics, namely age, sex, level of education, history of other psychiatric conditions, comorbidities, and medications. Together with neuroimaging characteristics, these will be used for response prediction.

    Time frame: 120 days

  3. Cognitive functioning/Spatial working Memory

    The test will be used measure spatial working memory. Memory span is the major outcome variable of this test (the longest number of elements correctly retraced). Higher values indicate better outcomes. Its minimum value is 0 and it has no theoretical maximum value.

    Time frame: 120 days

  4. Cognitive functioning/Executive function

    The test will be used measure executive functioning. Number of mistakes is the major outcome variable of this test (mistakes arise when subjects fail to differentiate a distractor from the continuous task). Higher values indicate worse outcomes. Its minimum value is 0 and it has no theoretical maximum value. Time Frame: 120 days

    Time frame: 120 days

  5. Cognitive functioning/reaction time

    The test will be used measure executive functioning and reaction time. Average reaction time is the major outcome variable of this test. Higher values indicate worse outcomes.

    Time frame: 120 days

  6. Clinical symptoms based on self-report questionnaires

    Beck depression inventories are to be used to monitor clinical symptoms of depression

    Time frame: 120 days

07

Study locations

1 of 1 sites recruiting
  • Department of Psychiatry and Psychotherapy
    Budapest, Pest County 1083, Hungary
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2028, 36 months after the start.

Of 136 non-industry interventional studies with no phase under Depressive Disorder, Treatment-Resistant, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 88. This study's planned 36 months is below that.

Counting every sponsor, half of 140 studies reached it within 50 months; a quarter within 22 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Oct 3, 2025
StartActual
Jun 13, 2025
Primary completionEst.
Jun 13, 2028
CompletionEst.
Jun 13, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Recruiting
changed Nov 17, 2026
Sites
Department of Psychiatry and Psychotherapy is now Recruiting
Nov 17, 2026
Contact
Study contact now listed: added c•••@semmelweis.hu · •••0174; added a•••@gmail.com · •••7816. See the current contact
Nov 17, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Department of Psychiatry and Psychotherapy · Budapest, HungaryContact added c•••@med.semmelweisuniv.hu · •••0174
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Enrolling by invitation→Recruiting
    Department of Psychiatry and Psychotherapy is now Recruiting
    Contact Study contact now listed: added c•••@semmelweis.hu · •••0174; added a•••@gmail.com · •••7816. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Department of Psychiatry and Psychotherapy · Budapest, HungaryContact added c•••@med.semmelweisuniv.hu · •••0174
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07207239
Responsible party
Gábor Csukly (Associate Professor, Semmelweis University) — Principal investigator
First posted
Oct 3, 2025
Start date
Jun 13, 2025
Primary completion
Jun 13, 2028 (estimated)
Completion
Jun 13, 2028 (estimated)
Last update
Nov 17, 2026

Study contacts

Gábor Csukly, MDd, Phd
Contact
csukly.gabor@semmelweis.hu
+36208250174
Árpád Fábián-Kovács
Contact
arpika929@gmail.com
+36306537816

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion